Cirius Therapeutics IPO

ciriustx.com

Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin sensitizer is used to treat nonalcoholic steatohepatitis which is characterized by buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.

Founded2015
Total Funding to Date$68.9MM
Register for Details

For more details on financing and valuation for Cirius Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Cirius Therapeutics Ticker Symbol

Cirius Therapeutics does not currently have an official ticker symbol because this company is still private. Register today to connect with our Private Market Specialists and learn more about new pre-IPO investment opportunities.

Cirius Therapeutics Stock Price

The stock price for Cirius Therapeutics will be known as it becomes public. Here are similar public companies: HealthStream (NAS: HSTM), Doximity (NYS: DOCS), Zymergen (NAS: ZY), Sight Sciences (NAS: SGHT).

Other companies like Cirius Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$317.32MM
Sector
 
 
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$1.08B